The stock market celebrates Genfit's Phase II results
Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and secondary endpoints while showing no adverse side-effects. It helped to improve insulin sensitivity in the liver and peripheral tissues. It is intended to treat non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). The product significantly reduced insulin-induced hepatic glucose production by 0.86 mg/kg/min from baseline to week 8 vs. 0.63 mg/kg/min for placebo (p=0.006). The single blinded trial in French centres enrolled 22 insulin-resistant patients with abdominal obesity. GFT505 is the most advanced compound of a group of drug candidates developed by Genfit. It targets multiple risk factors of pre-diabetes and diabetes: hyperglycaemia and insulin resistance, atherogenic dyslipidemia and inflammation, as well as certain liver disorders often associated with pre-diabetic and diabetic states. Genfit was founded in 1999 Loos/France. The company employs about 100 people and is listed at Alternext on the NYSE Euronext Stock Exchange. The biotech still owns global rights to all of its compounds.